Skip to search formSkip to main contentSkip to account menu

vadimezan

Known as: 5,6-dimethylxanthenone-4-acetic acid, 5,6-dimethyl xanthenone acetic acid, 5,6-MexXAA 
A fused tricyclic analogue of flavone acetic acid with potential antineoplastic activity. Vadimezan induces the cytokines tumor necrosis alpha (TNF… 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (3)

AS1404ASA 404NSC 640488

Broader (2)

Antineoplastic AgentsXanthones
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Anticancer potential of tumor vascular disrupting agents: review of the latest clinical evidence
Solid tumors differ from normal tissue by having a low vascular density, leading to various forms of vascular stress. Tumor… 
2010
2010
Abstract 24: Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA and evidence for redox signaling in its mode of action
DMXAA (5,6-dimethylxanthenone-4-acetic acid) is in late stages of clinical development as a tumor vascular disrupting agent. The… 
2010
2010
A safety and tolerability study of vadimezan in combination with docetaxel in Japanese patients with advanced or recurrent solid tumors.
e13106 Background: Vadimezan (ASA404; 5,6-dimethylxanthenone-4-acetic acid), is a novel tumor vascular disrupting agent. It… 
2010
2010
Cancer Therapy : Clinical Phase 1 First-inHuman Trial of the Vascular Disrupting Agent Plinabulin ( NPI-2358 ) in Patients with Solid Tumors or Lymphomas
Purpose: Plinabulin (NPI-2358) is a vascular disrupting agent that elicits tumor vascular endothelial architectural… 
2010
2010
Plasma biomarker analysis of a phase I trial of ASA404 (vadimezan) in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer (NSCLC).
e18035 Background: ASA404 (vadimezan, DMXAA) is a flavonoid, non-tubulin-binding tumor-vascular disrupting agent (Tumor- VDA… 
2008
2008
Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study
5007 Background: DMXAA (ASA404) is a novel tumor vascular disrupting agent. In animal models DMXAA has synergistic anti-tumor… 
2008
2008
Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404)
8072 Background: DMXAA (ASA404) is a tumor vascular disrupting agent recently evaluated in phase II trials in NSCLC. A randomized… 
2007
2007
Combination of the vascular disrupting agent DMXAA (AS1404) with bevacizumab and paclitaxel produces synergistic antitumor activity in lung cancer xenografts
4642 The anti-VEGF monoclonal antibody, bevacizumab, has been approved for use alongside chemotherapy in colorectal, non-small… 
2002
2002
Effects o f 5 ,6-Dimethylxant henone-4-Acetic A cid o n H uman Tumor M icrocirculation A ssessed b y D ynamic C ontrast- Enhanced M agnetic R esonance I maging
Purpose: 5,6-Dimethylxanthenone-4-acetic acid (DMXAA) causes vascular shutdown in preclinical models. Dynamic contrast-enhanced… 
1997
1997
Chemotherapy with DMXAA (5,6-dimethylxanthenone-4-acetic acid) in combination with CI-1010 (1H-imidazole-1-ethanol,alpha-[[(2-bromoethyl)amino]methyl]-2-nitro-,mon o-hydrobromide (R isomer)) against…
Because an enhanced therapeutic gain might be expected with co-administration of a hypoxic cell selective cytotoxin and a…